Objective: To analyze the bacterial biofilm (BF) formation in patients with malignancy undergoing double J stent indwelling and its influencing factors. Methods: A total of 167 patients with malignant tumors who received double J stent indwelling in the hospital from January 2018 to January 2021 were included in the study. The urine and double J stent samples were collected for bacterial identification and observed for BF formation on the surface of the urinary catheter under a scanning electron microscope (SEM). Univariate and multivariate logistic regression analyses were used to analyze the influencing factors of BF. Results: The BF formation rate was 34.73% (58/167). The BF formation rate of positive specimens cultured in urine and double J stent was significantly higher than that of negative ones (P<0.05). Staphylococcus was the main BF bacteria in double J stent and urine culture specimens, followed by Enterococcus, Pseudomonas, Enterobacter, and Acinetobacter. Compared with the non-BF group, the number of viable bacteria in the double J stent and urine and the catheterization time in the BF group rose markedly (P= 90d, and urinary tract infection were risk factors for BF formation in patients with malignancy undergoing double J stent indwelling (P<0.05). Conclusion: There is a high rate of BF formation in patients with malignancy undergoing double J stent indwelling, with Staphylococcus as the dominant species. Treatment requires enhanced urinary catheter management and nutritional status to inhibit BF formation and lower the rate of urinary catheter-related infections.

Background: The bone marrow (BM) microenvironment plays a crucial role in acute myeloid leukemia (AML), but the distribution and clinical significance of monocyte subsets within this compartment remain poorly characterized. This study aimed to investigate the composition of BM monocyte subpopulations and their relationship with systemic immunity and clinical outcomes in AML patients. Methods: We collected BM samples from 98 AML patients (including 23 newly diagnosed, 28 nonremission, and 47 complete remission [CR] cases) and 23 healthy controls (HCs). Using flow cytometry, we analyzed monocyte subsets (classical, intermediate, nonclassical) and monocytic myeloid‐derived suppressor cells (m‐MDSCs) in BM, along with T lymphocyte subsets in peripheral blood. Survival analysis was performed with 1‐year follow‐up data. Results: Both the proportion of intermediate monocytes and m‐MDSCs among total monocytes were significantly elevated in newly diagnosed AML patients compared to those in HCs ( p = 0.019 and p = 0.003, respectively) and CR ( p = 0.003 and p = 0.037, respectively). This elevation was followed by a gradual decrease from diagnosis to remission. Multivariate Cox regression identified intermediate monocyte percentage as an independent prognostic factor (HR = 4.170, p = 0.034). Kaplan–Meier analysis confirmed that higher intermediate monocyte levels predicted shorter overall survival (OS) ( p = 0.031) and leukemia‐free survival (LFS) ( p = 0.028). Importantly, negative correlations were observed between BM blasts and peripheral blood T‐cell percentage ( r = −0.467, p = 0.005) and CD8 ⁺ T cells ( r = −0.504, p = 0.002), and between intermediate monocytes among total monocytes and total T‐cell percentage ( r = −0.475, p = 0.004). Conclusions: BM monocyte subsets, particularly intermediate monocytes, serve as significant indicators of disease progression and survival in AML. Their correlation with peripheral T‐cell immunity suggests their potential role in modulating antileukemic immune responses. These findings highlight the prognostic value of BM monocyte profiling and provide insights for developing novel immunotherapeutic strategies in AML.

Background Recently, WHO has classified COVID-19 as a global pandemic disease, and it is still spreading rapidly around the world, but no specific medicine or vaccine for 2019-nCov has been developed so far. At present, the epidemic situation in China has been basically controlled. Methods Here we report 9 COVID-19 patients hospitalized in the First People's Hospital of Zigong City, Zigong, China. In addition to antiviral drug treatment and other supportive treatment, all of them received traditional Chinese medicine prescription according to the different conditions of each patient, and we collected the clinical data of the 9 patients and analyzed the outcome as a retrospective study. Results The curative effect is very significant, all the patients have been discharged from the hospital, and the shortest course of treatment is only 12 days. Conclusions Combined with the fact that other parts of China use Traditional Chinese Medicine, including Wuhan Cabin Hospital, we speculate that Chinese medicine plays an encouraging role in this process and may be an adjuvant therapy of COVID-19, which may bring some reference to the treatment of COVID-19 worldwide, in spite of the efficacy and definite conclusions still need further study.